Jokath

Timolol and Travoprost, the active ingredients in Jokath, are a beta‑blocker and a prostaglandin analog presented as eye drops for ocular use. They are employed to lower intra‑ocular pressure in patients with primary open‑angle glaucoma and ocular hypertension.

GNH USA supplies Jokath as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jokath is indicated for ocular conditions where reduction of intra‑ocular pressure is required. - Primary open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression. - Ocular hypertension: reduces pressure to prevent conversion to glaucoma. - Secondary open‑angle glaucoma: helps control pressure when other causes are present.

Jokath may cause ocular and systemic reactions.

Common Side Effects: - Eye irritation or burning sensation. - Conjunctival hyperemia (red eye). - Blurred vision. - Dry eye sensation. - Mild headache. - Transient visual disturbances.

Serious or Rare Side Effects: - Significant reduction in heart rate or bradycardia. - Severe allergic reaction (angio‑edema, anaphylaxis). - Persistent ocular inflammation or uveitis. - Worsening of asthma or chronic obstructive pulmonary disease. - Periorbital fat atrophy with long‑term use. - Darkening of iris or peri‑ocular skin.

Before prescribing Jokath, consider patient‑specific factors and monitor appropriately. - Cardiovascular disease: assess heart rate and blood pressure before initiation. - Respiratory conditions: avoid in patients with uncontrolled asthma or COPD. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Contact lens wearers: advise removal before instillation and waiting period before reinsertion. - Concomitant ocular medications: evaluate for additive IOP‑lowering effects. - Store at room temperature: keep in original container, protect from light and moisture.

Jokath can interact with systemic and ocular agents that affect intra‑ocular pressure or cardiovascular function.

Major Interactions (Avoid): - Non‑selective β‑blockers (oral or inhaled): may cause additive bradycardia or bronchospasm. - Systemic carbonic anhydrase inhibitors: excessive IOP reduction.

Moderate Interactions (Monitor Closely): - Sympathomimetic agents (e.g., epinephrine eye drops): may diminish IOP‑lowering effect. - Anticholinergic eye drops: possible reduced efficacy. - Systemic antihypertensives: monitor blood pressure for additive hypotensive effect.